news

Enzyme replacement therapy for alpha-mannosidosis gets FDA approval

3
SHARES

The first and only enzyme replacement therapy approved for alpha-mannosidosis in the US has been cleared for adult and paediatric patients.

First FDA approved enzyme replacement therapy for alpha-mannosidosis

The US Food and Drug Administration (FDA) has approved Lamzede® (velmanase alfa-tycv) for non-central nervous system manifestations of alpha-mannosidosis (AM) in adult and paediatric patients.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

AM is an ultra-rare, progressive lysosomal storage disorder caused by deficiency in the enzyme α-mannosidase. Giacomo Chiesi, Head of Chiesi Global Rare Diseases stated that symptoms of the disorder include “impaired hearing, speech and mobility that progress from childhood into adulthood.”

Chiesi added that the FDA’s approval represents a major milestone because “Lamzede is the first and only enzyme replacement therapy approved for alpha-mannosidosis in the US.”

What is Lamzede?

Lamzede is a recombinant form of human alpha-mannosidase intended to provide or supplement natural alpha-mannosidase, an enzyme involved in the degradation of mannose–rich oligosaccharides to prevent their accumulation in various tissues in the body.

European approval of Lamzede

In 2018, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting an EU marketing authorisation for Lamzede as a long-term enzyme replacement therapy for AM.

The same year also saw the Chiesi Group receive regulatory approval via a marketing authorisation from the European Commission for Lamzede for the treatment of non-neurological manifestations in patients with mild to moderate AM.

Treatments for alpha-mannosidosis

Currently, there is no cure for AM. Patients with milder forms of the disease can be offered symptom management as well as treatment for complications and physical therapy.

Share via
Share via